JP2024508545A5 - - Google Patents
Info
- Publication number
- JP2024508545A5 JP2024508545A5 JP2023553660A JP2023553660A JP2024508545A5 JP 2024508545 A5 JP2024508545 A5 JP 2024508545A5 JP 2023553660 A JP2023553660 A JP 2023553660A JP 2023553660 A JP2023553660 A JP 2023553660A JP 2024508545 A5 JP2024508545 A5 JP 2024508545A5
- Authority
- JP
- Japan
- Prior art keywords
- deuterium
- disorders
- hydrogen
- alkyl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163155634P | 2021-03-02 | 2021-03-02 | |
| US63/155,634 | 2021-03-02 | ||
| PCT/CA2022/050295 WO2022183287A1 (en) | 2021-03-02 | 2022-03-02 | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024508545A JP2024508545A (ja) | 2024-02-27 |
| JP2024508545A5 true JP2024508545A5 (enExample) | 2025-03-04 |
| JP7894380B2 JP7894380B2 (ja) | 2026-07-23 |
Family
ID=83153685
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023553660A Active JP7894380B2 (ja) | 2021-03-02 | 2022-03-02 | セロトニン作動性薬に関係する障害の治療に有用なセロトニン作動性薬としてのインドール誘導体 |
| JP2023553664A Pending JP2024508922A (ja) | 2021-03-02 | 2022-03-02 | セロトニン作動性薬に関係する障害の治療に有用なセロトニン作動性薬としてのインドール誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023553664A Pending JP2024508922A (ja) | 2021-03-02 | 2022-03-02 | セロトニン作動性薬に関係する障害の治療に有用なセロトニン作動性薬としてのインドール誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20240166599A1 (enExample) |
| EP (2) | EP4301730A4 (enExample) |
| JP (2) | JP7894380B2 (enExample) |
| KR (2) | KR20230154219A (enExample) |
| CN (2) | CN117500788A (enExample) |
| AU (2) | AU2022229695A1 (enExample) |
| BR (1) | BR112023017754A2 (enExample) |
| CA (2) | CA3210270A1 (enExample) |
| IL (2) | IL305481A (enExample) |
| MX (2) | MX2023010317A (enExample) |
| WO (2) | WO2022183287A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| MX2024008691A (es) * | 2022-01-14 | 2024-07-19 | Cybin Irl Ltd | Composiciones y metodos de triptamina. |
| CA3265884A1 (en) * | 2022-08-31 | 2024-03-07 | Cybin Irl Limited | TRYPTAMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE |
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
| TW202519206A (zh) * | 2023-11-06 | 2025-05-16 | 大陸商宜昌人福藥業有限責任公司 | 一種n,n-二甲基色胺衍生物及其藥物組合物、製備方法和用途 |
| WO2025104490A1 (en) * | 2023-11-14 | 2025-05-22 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
| WO2025104491A1 (en) * | 2023-11-14 | 2025-05-22 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5578612A (en) * | 1990-10-15 | 1996-11-26 | Pfizer Inc. | Indole derivatives |
| HU225055B1 (en) * | 1990-10-15 | 2006-05-29 | Pfizer | Indole derivatives, their intermediates, process for production them and pharmaceutical compositions containing the compounds |
| ES2566056T3 (es) * | 2001-03-29 | 2016-04-08 | Eli Lilly And Company | N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6 |
| TWI318621B (en) * | 2006-08-03 | 2009-12-21 | Nat Bureau Of Controlled Drugs Dept Of Health | A series of deuterium labelled compounds as drug testing standards and their preparations |
| US20090062367A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched eletriptan |
| DK2753605T3 (da) * | 2011-09-09 | 2019-06-17 | Lantheus Medical Imaging Inc | Sammensætninger, fremgangsmåder, og systemer til syntesen og anvendelsen af billeddannelsesmidler |
| WO2018094106A2 (en) * | 2016-11-16 | 2018-05-24 | University Of South Florida | ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES |
| US12616706B2 (en) * | 2019-03-07 | 2026-05-05 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| MX2022009527A (es) * | 2020-02-04 | 2022-11-16 | Mindset Pharma Inc | Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. |
| AU2021215709A1 (en) * | 2020-02-04 | 2022-09-01 | Mindset Pharma Inc. | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders |
| WO2021218896A1 (zh) * | 2020-04-26 | 2021-11-04 | 江苏恒瑞医药股份有限公司 | 海鞘素类衍生物及其制备方法与医药用途 |
| IL312785B2 (en) * | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
-
2022
- 2022-03-02 MX MX2023010317A patent/MX2023010317A/es unknown
- 2022-03-02 AU AU2022229695A patent/AU2022229695A1/en active Pending
- 2022-03-02 IL IL305481A patent/IL305481A/en unknown
- 2022-03-02 KR KR1020237033351A patent/KR20230154219A/ko active Pending
- 2022-03-02 AU AU2022229037A patent/AU2022229037A1/en active Pending
- 2022-03-02 EP EP22762289.1A patent/EP4301730A4/en active Pending
- 2022-03-02 WO PCT/CA2022/050295 patent/WO2022183287A1/en not_active Ceased
- 2022-03-02 MX MX2023010316A patent/MX2023010316A/es unknown
- 2022-03-02 KR KR1020237033368A patent/KR20230154220A/ko active Pending
- 2022-03-02 JP JP2023553660A patent/JP7894380B2/ja active Active
- 2022-03-02 WO PCT/CA2022/050296 patent/WO2022183288A1/en not_active Ceased
- 2022-03-02 EP EP22762290.9A patent/EP4301747A4/en active Pending
- 2022-03-02 IL IL305622A patent/IL305622A/en unknown
- 2022-03-02 CN CN202280032370.6A patent/CN117500788A/zh active Pending
- 2022-03-02 US US18/279,290 patent/US20240166599A1/en active Pending
- 2022-03-02 CA CA3210270A patent/CA3210270A1/en active Pending
- 2022-03-02 US US18/279,293 patent/US20240166630A1/en active Pending
- 2022-03-02 CA CA3210275A patent/CA3210275A1/en active Pending
- 2022-03-02 CN CN202280032373.XA patent/CN117242065A/zh active Pending
- 2022-03-02 BR BR112023017754A patent/BR112023017754A2/pt unknown
- 2022-03-02 JP JP2023553664A patent/JP2024508922A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023513679A5 (enExample) | ||
| JP2024508922A5 (enExample) | ||
| JP2023512821A5 (enExample) | ||
| RU2119484C1 (ru) | Тропонзамещенный фенилоксазолидинон или его фармацевтически приемлемые соли или гидраты | |
| IL295371A (en) | Psilocyin derivatives as serotonergic psychedelics for the treatment of central nervous system disorders | |
| US5574055A (en) | Oxazolidinone derivatives | |
| JP2023553094A5 (enExample) | ||
| JP6321825B2 (ja) | 神経形成を刺激することができるｎ−フェニル−ラクタム誘導体及び神経障害の処置におけるそれらの使用 | |
| UY24375A1 (es) | Procedimiento para la preparacion de derivados de quinolin-4 -carboxamida | |
| AR068049A1 (es) | El uso de derivados de benzamida para el tratamiento de trastornos del snc y los mencionados derivados de benzamida. | |
| JP2018065830A (ja) | ヘテロアリール化合物およびそれらの使用方法 | |
| CA2428039A1 (en) | Serotonergic agents | |
| JP2024543973A5 (enExample) | ||
| JP2025513462A5 (enExample) | ||
| RU2013124827A (ru) | Производные индола и способ их получения | |
| JP2025513461A5 (enExample) | ||
| JP2021534099A (ja) | 神経変性疾患を治療するためのＰｐａｒｇｃ１ａ活性化剤としての２‐アリールベンゾイミダゾール | |
| JP2025502614A5 (enExample) | ||
| JP3856829B2 (ja) | オキサゾリジノン誘導体、その製造及び治療的使用 | |
| MXPA04003968A (es) | Compuestos de silicio. | |
| AR059182A1 (es) | Utilizacion de 2-imidazoles para el tratamiento de trastornos del snc,proceso para obtener los compuestos | |
| JP2008508251A5 (enExample) | ||
| JP5947907B2 (ja) | Ｋｃｎｑカリウムチャネル作動薬として使用できる新規な化合物、その製造方法および用途 | |
| US6696450B2 (en) | Serotonergic agents with long-acting in vivo effects | |
| FR2791346A1 (fr) | Nouveaux derives de morpholine, procede pour leur preparation et compositions pharmaceutiques les contenant |